Alzheimer's Disease: Potential Benefit of Isoflavones
Alzheimer's Disease
About this trial
This is an interventional treatment trial for Alzheimer's Disease
Eligibility Criteria
Inclusion Criteria: Diagnosis of probable AD Has reliable and available caregiver to assist with medication and appointments On a stable dose of cholinesterase inhibitor, or if unable to tolerate medication, patient has no plans to re-initiate cholinergic therapies while in the study Exclusion Criteria: Current or recent use (<6 months) of menopausal Hormone Replacement Therapy (HRT) Current or recent use (<4 months) or oral antibiotic therapy Typical dietary intake of soy isoflavones >5 mg/day History or significant gastro-intestinal or colon disease, or colon/intestinal resection Irritable bowel syndrome History of breast cancer, or abnormal mammogram within 12 months History of chronic obstructive pulmonary disease, diabetes mellitus, liver disease or unstable ischemic heart disease Significant neurological disease other than AD that might affect cognitive function, such as stroke, Parkinson's disease, multiple sclerosis, or serious traumatic brain injury
Sites / Locations
- University of Wisconsin
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Novasoy treated
Placebo
100mg/day soy isoflavones
100mg/day matching placebo